Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Watkin Jones shares fall as 'challenging market backdrop' continues

(Sharecast News) - Residential property management firm Watkin Jones saw its share price drop sharply on Thursday after reporting that transactional activity "remains slow" following a big drop in revenues in its first half. Against a backdrop of "continuing limited transactional liquidity in the market", the group reported revenues of £129.2m over the six months to 31 March, down 26% from £175.1m the year before.

Adjusted pre-tax profits fell to just £0.2m, compared with a profit of £3.4m previously, though statutory results showed a pre-tax loss of £0.9m, down from a profit of £2.1m before, due to a £1.1m exceptional finance cost related to the unwinding of the discount rate on a Building Safety provision.

No interim dividend was paid as the board decided to "prioritis[e] the maintenance of financial flexibility", it said.

Chief executive Alex Pease said results were in line with the company's expectations "despite the continuing challenging market backdrop, as a result of our focus on operational delivery, cost management and cash generation".

He continued: "Whilst transactional activity remains slow and subject to a continuing volatile market backdrop, we are focussed on ensuring that the group remains in the best position to exploit opportunities as conditions improve."

Shares were 11.6% lower at 31.6p by 0837 BST.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.